Sign Out
Monoclonal Antibodies.
Pharmacology: Pharmacodynamics: Mechanism of Action: Rituximab is a chimeric mouse/human monoclonal antibody that binds specifically to the transmembrane antigen CD20. This antigen is located on pre-B- and mature B-lymphocytes, but not on hemopoietic stem cells, pro-B-cells, normal plasma cells, or other normal tissue. Rituximab binds to the CD20 antigen on B-lymphocytes and initiates immunologic reactions that mediate B-cell lysis.
Pharmacokinetics: Elimination: Mean terminal elimination half-life - approximately 20 days.
Pharmacokinetics in Special Populations: No pharmacokinetics data are available in patients with hepatic or renal impairment.
Continue with Google